The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example - Dickinson, Gemma L.; Lennard, Martin S.; Tucker, Geoffrey T.; Rostami‐Hodjegan, Amin (British journal of clinical pharmacology, 2007)
Keywords: Anticoagulants - administration & dosage; Anticoagulants - pharmacokinetics; Aryl Hydrocarbon Hydroxylases - genetics; Biological and medical sciences; Blood Coagulation - genetics; clinical trial simulation; Cytochrome P-450 CYP2C9; cytochrome P450; drug metabolism; Genotype; Humans; in silico; Medical sciences; modelling and simulation; Models, Biological; pharmacogenetics; Pharmacokinetics & Pharmacodynamics; Pharmacology. Drug treatments; Polymorphism, Genetic; Warfarin - administration & dosage; Warfarin - pharmacokinetics; Human; Drug; Pharmacogenetics; Warfarin; Enzyme; Isozyme; Coumarine derivatives; Cytochrome P450; Anticoagulant; Metabolism; Silica; Antivitamin K; Simulation; drug metabolism; Genetics; Clinical trial; modelling and simulation; Pharmacokinetics; in silica; CYP2C9 gene; clinical trial simulation